Compare PNC Financial Services Group Inc. (The) Common Stock (PNC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PNC Financial Services Group Inc. (The) Common Stock vs Repligen Corporation Common Stock — how do they compare? PNC Financial Services Group Inc. (The) Common Stock trades at $211.49 (market cap $86.09B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: PNC Financial Services Group Inc. (The) Common Stock is far larger — about 7.6× Repligen Corporation Common Stock's market cap, and PNC Financial Services Group Inc. (The) Common Stock pays a 3.71% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals.
| PNC | RGEN | |
|---|---|---|
Market Cap | $86.09B | $11.31B |
Volume | 3,223,582 | 1,216,919 |
Sector | Financials | Health |
52-Week High | $256.97 | $194.57 |
52-Week Low | $178.37 | $102.87 |
Enterprise Value | $143.07B | $11.20B |
Dividend Yield | 3.71% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PNC trades at $219.48, down 0.8% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $23.08B in 2025, with net income of $6.94B and a robust net income margin of 31.06%. Analyst consensus is a Buy with a $276.13 price target, indicating significant upside potential from current levels.
The outlook for PNC is positive given its earnings momentum and attractive valuation (P/E of 12.09), though risks include regulatory scrutiny and net cash outflows from investing activities. The stock offers a dividend yield supported by recent increases, positioning it as a value opportunity in the financial sector amid current bearish technical indicators.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PNC Financial Services Group Inc. (The) Common Stock
PNC Financial Services Group is a financial services holding company. Its businesses include retail banking, corporate and institutional banking, and asset management.
Read more on PNC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
